» Articles » PMID: 27054363

Mutational History of a Human Cell Lineage from Somatic to Induced Pluripotent Stem Cells

Overview
Journal PLoS Genet
Specialty Genetics
Date 2016 Apr 8
PMID 27054363
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

The accuracy of replicating the genetic code is fundamental. DNA repair mechanisms protect the fidelity of the genome ensuring a low error rate between generations. This sustains the similarity of individuals whilst providing a repertoire of variants for evolution. The mutation rate in the human genome has recently been measured to be 50-70 de novo single nucleotide variants (SNVs) between generations. During development mutations accumulate in somatic cells so that an organism is a mosaic. However, variation within a tissue and between tissues has not been analysed. By reprogramming somatic cells into induced pluripotent stem cells (iPSCs), their genomes and the associated mutational history are captured. By sequencing the genomes of polyclonal and monoclonal somatic cells and derived iPSCs we have determined the mutation rates and show how the patterns change from a somatic lineage in vivo through to iPSCs. Somatic cells have a mutation rate of 14 SNVs per cell per generation while iPSCs exhibited a ten-fold lower rate. Analyses of mutational signatures suggested that deamination of methylated cytosine may be the major mutagenic source in vivo, whilst oxidative DNA damage becomes dominant in vitro. Our results provide insights for better understanding of mutational processes and lineage relationships between human somatic cells. Furthermore it provides a foundation for interpretation of elevated mutation rates and patterns in cancer.

Citing Articles

Widespread mutagenesis and chromosomal instability shape somatic genomes in systemic sclerosis.

Vijayraghavan S, Blouin T, McCollum J, Porcher L, Virard F, Zavadil J Nat Commun. 2024; 15(1):8889.

PMID: 39406724 PMC: 11480385. DOI: 10.1038/s41467-024-53332-z.


Considerations for the development of iPSC-derived cell therapies: a review of key challenges by the JSRM-ISCT iPSC Committee.

Madrid M, Lakshmipathy U, Zhang X, Bharti K, Wall D, Sato Y Cytotherapy. 2024; 26(11):1382-1399.

PMID: 38958627 PMC: 11471376. DOI: 10.1016/j.jcyt.2024.05.022.


iPS cell generation-associated point mutations include many C > T substitutions via different cytosine modification mechanisms.

Araki R, Suga T, Hoki Y, Imadome K, Sunayama M, Kamimura S Nat Commun. 2024; 15(1):4946.

PMID: 38862540 PMC: 11166658. DOI: 10.1038/s41467-024-49335-5.


Somatic mutations in aging and disease.

Ren P, Zhang J, Vijg J Geroscience. 2024; 46(5):5171-5189.

PMID: 38488948 PMC: 11336144. DOI: 10.1007/s11357-024-01113-3.


Enrichment of Deleterious Mutated Genes Involved in Ciliary Function and Histone Modification in Brain Cancer Patient-Derived Xenograft Models.

Jeong H, Moon H, Yun S, Cho S, Park H, Park S Biomedicines. 2023; 11(11).

PMID: 38001935 PMC: 10669283. DOI: 10.3390/biomedicines11112934.


References
1.
Geti I, Ormiston M, Rouhani F, Toshner M, Movassagh M, Nichols J . A practical and efficient cellular substrate for the generation of induced pluripotent stem cells from adults: blood-derived endothelial progenitor cells. Stem Cells Transl Med. 2013; 1(12):855-65. PMC: 3659672. DOI: 10.5966/sctm.2012-0093. View

2.
Alexandrov L, Nik-Zainal S, Wedge D, Aparicio S, Behjati S, Biankin A . Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415-21. PMC: 3776390. DOI: 10.1038/nature12477. View

3.
Kong A, Frigge M, Masson G, Besenbacher S, Sulem P, Magnusson G . Rate of de novo mutations and the importance of father's age to disease risk. Nature. 2012; 488(7412):471-5. PMC: 3548427. DOI: 10.1038/nature11396. View

4.
Nik-Zainal S, Alexandrov L, Wedge D, Van Loo P, Greenman C, Raine K . Mutational processes molding the genomes of 21 breast cancers. Cell. 2012; 149(5):979-93. PMC: 3414841. DOI: 10.1016/j.cell.2012.04.024. View

5.
Yusa K, Rashid S, Strick-Marchand H, Varela I, Liu P, Paschon D . Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature. 2011; 478(7369):391-4. PMC: 3198846. DOI: 10.1038/nature10424. View